Search Result

Results for "

Glycolic acid

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Apoptosis (1) Biochemical Assay Reagents (8) COX (2) Endogenous Metabolite (3) FLT3 (1) Fluorescent Dye (1) Isotope-Labeled Compounds (1) PROTACs (1) Tyrosinase (3)
By Research Areas:	Cancer (5) Inflammation/Immunology (2) Metabolic Disease (4)
Oligonucleotides:	Polymers (5)

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Oligonucleotides

Targets Recommended: Amino acid Transporter Amino Acid Derivatives Hydroxycarboxylic Acid Receptor (HCAR) Free Fatty Acid Receptor Fatty Acid Synthase (FASN) Apical Sodium-Dependent Bile Acid Transporter G protein-coupled Bile Acid Receptor 1

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W015967

Glycolic acid Hydroxyethanoic acid	Endogenous Metabolite Tyrosinase	Metabolic Disease
Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-W015967S

Glycolic acid-d2	Endogenous Metabolite Tyrosinase	Metabolic Disease
Glycolic acid-d₂ is the deuterium labeled Glycolic acid. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-22166

Glycolic acid oxidase inhibitor 1	Others	Metabolic Disease
Glycolic acid oxidase inhibitor 1 is a glycolate oxidase inhibitor, extracted from patent EP0021228A1, in Table IV.

HY-B2247

PLGA (50:50) 10+ Cited Publications poly(lactic-co-Glycolic acid) (50:50)	Biochemical Assay Reagents	Others
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.

HY-B2247A

PLGA (75:25) poly(lactic-co-Glycolic acid) (75:25)	Biochemical Assay Reagents	Others
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .

HY-B0482

Acemetacin TVX 1322	COX	Inflammation/Immunology
Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.

HY-158255A

mPEG-PLGA (22500-26500)	Biochemical Assay Reagents	Others
mPEG-PLGA (22500-26500) is a biodegradable polymer composed of methyl polyethylene glycol (mPEG) and poly(lactic-co-glycolic acid) (PLGA). mPEG-PLGA (22500-26500) can be used in drug delivery systems .

HY-W015967R

Glycolic acid (Standard) Hydroxyethanoic acid (Standard)	Endogenous Metabolite Tyrosinase	Metabolic Disease
Glycolic acid (Standard) is the analytical standard of Glycolic acid. This product is intended for research and analytical applications. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-W778203

Glycolic acid-13C2 Hydroxyethanoic acid-¹³C₂	Isotope-Labeled Compounds	Others
Glycolic acid- ¹³C₂ is the ¹³C-labeled Glycolic acid (HY-W015967). Glycolic acid- ¹³C₂ is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-B0482R

Acemetacin (Standard)	COX	Inflammation/Immunology
Acemetacin (Standard) is the analytical standard of Acemetacin. This product is intended for research and analytical applications. Acemetacin (TVX 1322) is a non-steroidal anti-inflammatory drug and a glycolic acid ester of indometacin that is a cyclooxygenase inhibitor.

HY-148775A

mPEG-PLGA (21500-26500)	Biochemical Assay Reagents	Others
mPEG-PLGA (21500-26500) is a biodegradable polymer composed of methyl polyethylene glycol (mPEG) and poly(lactic-co-glycolic acid) (PLGA). mPEG-PLGA (21500-26500) can be used in drug delivery systems .

HY-158089

PLGA-COOH (MW 80000) (LA/GA 50:50)	Biochemical Assay Reagents	Others
PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer, which consist of lactic acid (LA)-glycolic acid (GA) with a molar ratio of 50:50, and a carboxyl terminal groups. PLGA-COOH (MW 80000) (LA/GA 50:50) is utilized in drug delivery system for its biocompatibility and biodegradability .

HY-D0153

Tetramethylrhodamine-5-isothiocyanate	Fluorescent Dye	Cancer
Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles .

HY-157213

LWY713	Apoptosis PROTACs FLT3	Cancer
LWY713 is a PROTAC-class FLT3 degrader (DC₅₀=0.64 nM), which selectively induces FLT3 degradation via cereblon and proteasome-dependent pathways. LWY713 inhibits cell proliferation and induces G0/G1 phase arrest and apoptosis in MV4-11 cells. LWY713 shows effective in vivo antitumor activity in MV4-11 xenograft models . LWY713 consists of a target protein ligand (red part) Gilteritinib (HY-12432), an E3 ubiquitin ligase ligand (blue part) Lenalidomide-F (HY-W039233), and a PROTAC linker (black part) Glycolic acid (HY-W015967). E3 ubiquitin ligase and linker can form Lenalidomide-Glycolic acid (HY-169373); the active control for the target protein ligand is Naproxen Gilteritinib (HY-169374).

HY-156829

PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1)	Others	Cancer
PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) is a matrix materia, with lactic acid (LA)：glycolic acid (GA) = 1:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 1:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .

HY-156829A

PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1)	Others	Cancer
PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) is a matrix materia, with lactic acid (LA)：glycolic acid (GA) = 15:1, that acts as anti-cancer drug delivery. PLGA-PEG-PLGA (1500-1500-1500) (LA/GA 15:1) can improve a drug's bioavailability, efficacy, water solubility, drug encapsulation efficiency, sustained drug release, and to minimize undesirable toxicity .

HY-148775

PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)	Biochemical Assay Reagents	Others
PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .

HY-148775B

PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60)	Biochemical Assay Reagents	Others
PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 40:60) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .

HY-148776

PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)	Biochemical Assay Reagents	Others
PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .

HY-19873

SL-052	Others	Cancer
SL-052 is a hypocrellin-based photosensitizer that has recently shown promising results in clinical and preclinical testing for cancer photodynamic therapy (PDT). SL-052 is encapsulated in biodegradable polylactic-co-glycolic acid (PLGA) polymer nanoparticles optimized using single emulsion solvent evaporation technology. The SL-052-PLGA nanoparticles were more effective in PDT treatment of subcutaneous SCCVII squamous cell carcinoma compared to polyvinylpyrrolidone (PVP)-based and standard liposomal SL-052 formulations. A longer time interval between drug injection and tumor illumination can improve tumor cure rates, and SL-052-PLGA nanoparticles showed the best therapeutic effect among all SL-052 formulations.

Cat. No.	Product Name	Type

HY-D0153

Tetramethylrhodamine-5-isothiocyanate	Fluorescent Dyes/Probes
Tetramethylrhodamine-5-isothiocyanate is a potent fluorescent dye. Tetramethylrhodamine-5-isothiocyanate can be used for label PG-M3 antibody for rapid diagnosis of acute promyelocytic leukemia (APL). Tetramethylrhodamine-5-isothiocyanate can be used as probe to quantify in vivo the biodistribution of PLGA (poly(lactic-co-glycolic) acid) and PLGA/chitosan nanoparticles .

Cat. No.	Product Name	Type

HY-B2247

PLGA (50:50) 10+ Cited Publications poly(lactic-co-Glycolic acid) (50:50)	Drug Delivery
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-W015967

Glycolic acid Hydroxyethanoic acid	Structural Classification Immune System Disorder Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Disease markers Endocrine diseases Metabolic Disease Nervous System Disorder Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite Tyrosinase
Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-W015967R

Glycolic acid (Standard) Hydroxyethanoic acid (Standard)	Structural Classification Immune System Disorder Microorganisms Ketones, Aldehydes, Acids Disease markers Endocrine diseases Nervous System Disorder Endogenous metabolite Cancer	Endogenous Metabolite Tyrosinase
Glycolic acid (Standard) is the analytical standard of Glycolic acid. This product is intended for research and analytical applications. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

Cat. No.	Product Name	Chemical Structure

HY-W015967S

Glycolic acid-d2
Glycolic acid-d₂ is the deuterium labeled Glycolic acid. Glycolic acid is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

HY-W778203

Glycolic acid-13C2
Glycolic acid- ¹³C₂ is the ¹³C-labeled Glycolic acid (HY-W015967). Glycolic acid- ¹³C₂ is an inhibitor of tyrosinase, suppressing melanin formation and lead to a lightening of skin colour.

Cat. No.	Product Name		Classification

HY-B2247

PLGA (50:50) 10+ Cited Publications poly(lactic-co-Glycolic acid) (50:50)		Polymers
PLGA (50:50) (poly(lactic-co-glycolic acid) (50:50)) is a copolymer of poly lactic acid (PLA) and poly glycolic acid (PGA) which can be used to fabricate devices for drug delivery and tissue engineering applications.

HY-B2247A

PLGA (75:25) poly(lactic-co-Glycolic acid) (75:25)		Polymers
PLGA (75:25) is a low toxicity, biocompatible and biodegradable controlled drug delivery carrier, can achieve slow release in the organism. PLGA (75:25) is a copolymer of 75% poly lactic acid (PLA) and 25% poly glycolic acid (PGA). PLGA (75:25) has been extensively studied as delivery vehicles for agents, proteins and various other macromolecules such as DNA, RNA and peptides .

HY-158089

PLGA-COOH (MW 80000) (LA/GA 50:50)		Polymers
PLGA-COOH (MW 80000) (LA/GA 50:50) is a copolymer, which consist of lactic acid (LA)-glycolic acid (GA) with a molar ratio of 50:50, and a carboxyl terminal groups. PLGA-COOH (MW 80000) (LA/GA 50:50) is utilized in drug delivery system for its biocompatibility and biodegradability .

HY-148775

PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25)		Polymers
PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (60kDA-3.4kDA, LA:GA ratio 75:25) has a molecular weight of 60kDA to 3.4kDA and contains a 75:25 ratio of lactic acid (LA) to glycolic acid (GA) molecules .

HY-148776

PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50)		Polymers
PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) is a kind of poly(lactide-co-glycolide)-block-poly(ethylene glycol) (PLGA-PEG-Mal) nanoparticles. PLGA-PEG-MAL (20kDA-5.0kDA, LA:GA ratio 50:50) has a molecular weight of 20kDA to 5.0kDA and contains a 50:50 ratio of lactic acid (LA) to glycolic acid (GA) molecules. The molecular ratio of LA to GA determines the rate of matrix degradation and protein re-release .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Glycolic acid

Inhibitors & Agonists

Fluorescent Dye

Biochemical Assay Reagents

NaturalProducts

Isotope-Labeled Compounds

Oligonucleotides

Natural
Products